NASDAQ:ASNS - Arsanis, Inc.
$2.76
 $0.00
0.00%
1:45PM EDT
2019-02-15
Arsanis, Inc., incorporated on August 2, 2010, is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company's mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500. The Companys lead program, ASN100, is being studied to prevent hospital-acquired Staphylococcus aureus pneumonia in mechanically ventilated patients heavily colonized with Staphylococcus aureus in their respiratory tracts. The ASN100 is in Phase II clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. Its ASN200 addresses the unmet medical need caused by drug-resistant extra-intestinal escherichia coli infections. ASN200 is for Escherichia coli, apply a precise and multi-modal mAb approach against novel targets to allow for potential use in both preventive and treatment settings, with a goal of providing safe and effective alternatives to small molecule antibiotics, particularly against multi-drug resistant strains. The ASN300 addresses the unmet medical need due to carbapenem-resistant klebsiella pneumoniae infections. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ASNS     avg for
industry  
  avg for
sector  
42 stocks weight:  -1000. 00   0. 00   0. 00  
42 stocks rank:  4. 04 K 1. 86 K 1. 09 K
# analyst opinions:  1. 00   14. 92   14. 43  
mean recommendation:  3. 00   1. 91   1. 93  

quick ratio:  4. 93   5. 37   1. 81  
current ratio:  5. 08   5. 69   2. 19  

target price low:  2. 00   88. 97   117. 82  
target price avg:  2. 00   115. 19   141. 96  
target price high:  2. 00   143. 40   163. 16  
1-yr high:  26. 03   124. 30   142. 77  
last close:  2. 76   101. 85   127. 84  
50-day avg:  3. 10   98. 27   122. 46  
200-day avg:  5. 66   99. 72   122. 70  
1-yr low:  1. 16   78. 19   100. 16  
volume:  70. 84 K 2. 38 M 4. 64 M
50-day avg volume:  599. 40 K 3. 31 M 4. 94 M
200-day avg volume:  702. 25 K 3. 23 M 4. 28 M

1-day return:  2. 99 % 0. 22 % 0. 48 %
this week return:  2. 60 % 1. 77 % 2. 01 %
12-wk return:  122. 58 % 6. 56 % 3. 33 %
52-wk return:  -79. 29 % -2. 23 % 14. 35 %

enterprise value (EV):  9. 35 M 55. 17 B 104. 51 B
market cap:  39. 52 M 49. 01 B 96. 46 B
EBITDA:  -47. 45 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -0. 20   -91. 79   2. 29  
total debt:  10. 73 M 13. 73 B 16. 57 B
debt/equity:  38. 48   258. 01   110. 73  
net income (common):  -44. 86 M 2. 37 B 3. 58 B

shares outstanding:  14. 32 M 607. 99 M 1. 22 B
shares:  4. 92 M 605. 53 M 1. 15 B
shares short:  662. 96 K 11. 62 M 12. 55 M
shares short prior month:  578. 95 K 11. 95 M 13. 44 M
short ratio:  1. 51   4. 82   3. 10  
short % of float:  18. 39 % 6. 19 % 2. 82 %
total cash/share:  2. 85   12. 02   11. 46  
total cash:  40. 75 M 7. 41 B 7. 37 B
free cash flow:  -29. 48 M 95. 99 M 2. 04 B
operating cash flow:  -46. 72 M 164. 74 M 3. 04 B

book value:  1. 95   14. 43   28. 26  
price/book:  1. 42   -1. 57   -2. 97  
operating margins:  0. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  255. 17 % --- ---
1-yr mean volatility:  0. 42 % 0. 01 % 0. 06 %

1-yr EPS:  -3. 62   3. 03   4. 09  
forward EPS:  -2. 28   4. 33   6. 99  
P/E:  -0. 76   6. 11   26. 91  
forward P/E:  -1. 18   8. 38   10. 48  
PE/G:  0. 02   0. 37   5. 61  
growth:  -31. 06 % 683. 72 % 104. 79 %
earnings high:  -0. 74   1. 27   1. 66  
earnings avg:  -0. 74   1. 01   1. 53  
earnings low:  -0. 74   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -71. 66 % -3. 27 % 3. 81 %
return on equity:  -227. 11 % 107. 48 % 27. 82 %

beta (1yr vs S&P500):  0. 16   1. 21   0. 93  
sharpe (1yr):  0. 37   0. 06   0. 98  

held % insiders:  54. 91 % 6. 46 % 3. 21 %
held % institutions:  75. 23 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : ASNS
.        + 0 =             0 :: INITIAL WEIGHT
.  + 141.964 =       141.964 :: inverse volume-to-price addition
.  + 277.088 =       419.052 :: spline projection addition
.  - 250.931 =       168.121 :: poor performance penalty
.    x 0.515 =        86.656 :: one-year gains+dividend factor
.    x 3.093 =       268.004 :: 13 weeks' performance factor
.    x 1.492 =       399.993 :: industry recommendation factor
.    x 1.142 =       456.629 :: symbol recommendation factor
.    x 0.993 =       453.356 :: return on assets factor
.    x 0.977 =        443.06 :: return on equity factor
.    x 2.892 =      1281.124 :: current ratio factor
.     x 1.12 =        1435.0 :: quick ratio factor
.    x 1.289 =      1850.122 :: short ratio factor
.    x 2.014 =      3726.443 :: price-to-book factor
.    x 1.072 =      3994.678 :: debt-to-equity factor
.    x 2.173 =      8678.808 :: P/E weight
.    x 2.209 =     19171.132 :: PE/G factor
.    x 1.563 =     29965.885 :: beta factor
.    x 0.372 =     11142.133 :: sharpe factor
.    x 0.948 =     10557.449 :: target low factor
.    x 0.907 =      9575.507 :: target mean factor
.    x 0.948 =      9073.032 :: target high factor
.    x 1.066 =      9668.339 :: industry 12-weeks return
.    x 0.955 =      9236.069 :: overall "drift" factor
.    x 0.997 =      9205.668 :: largest single-day jump factor
.    x 0.069 =       638.396 :: low price factor
.      x 1.0 =       638.439 :: factor hist industry gain for week 06
.   cubeRoot =         8.611 :: reduced for readability
.                   -999.999 :: FINAL WEIGHT for NASDAQ:ASNS


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org